FREMONT, Calif., May 31, 2012 /PRNewswire/ -- Velos, Inc. today announced the release of Velos Aversi, an iPad app for clinicians in oncology and bone marrow transplantation. The app is now available for download on the Apple App Store.
On Saturday, June 2, 20127:00 am CDT at the 2012 ASCO Annual Meeting in Chicago, Illinois, Dr. Roy Jones, MD, PhD, from the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center in Houston, Texas, will give a talk on the approach to improving patient safety, care, and adverse event management with Velos Aversi. Demonstrations of Velos Aversi will also be available at the Velos ASCO booth (#19118) throughout the conference.
Velos Aversi is designed to record, track, and export patient adverse events (AE) and Graft-Versus-Host Disease (GVHD) at point-of-care in hospital and ambulatory care settings. With a few touches on the iPad, clinicians, physicians, and research nurses can review and manage their patients' AE and GVHD histories anytime, anywherefreeing them from large and cumbersome paper files. The app allows for more accurate attribution and reduces transcription errors that can occur when AE data entry is delayed. Direct and immediate input by clinicians saves time and ensures the quality of the record, particularly when grading events. Reliance on static, unconnected documents and systems to record AEs and GVHD in clinical trials and after transplants has been costly in terms of missed events, failure to record, multiple duplicate records, variations on scale or grade, and the need to review multiple streams of data (labs, notes, etc.) prior to recording an event.
Velos Aversi solves these problems through pre-loaded AE or GVHD scores from previous patient encounters and combined data collection for AEs and GVHD. Velos Aversi is also available in tandem with other Velos offerings, including Velos eResearch. Velos now offers a suite of products that tracks labs, adverse events, and appropriate rules and workflows.
"It's an exciting time to be in the healthcare information technology field," said John McIlwain, CEO and President of Velos. "With Velos Aversi, we are bringing adverse event and safety information to the palm of the clinician's hand. Clinicians needed a simple, no-nonsense way to manage adverse events. That's Velos Aversi."
There has been growing interest and feedback from clinicians over the past few months since Velos Aversi was first unveiled to the bone marrow transplant community at the 2012 Blood and Marrow Transplantation (BMT) Tandem Meetings in February 2012. Velos continues to encourage the user community to send additional feedback to email@example.com.
About Velos Velos is thetrusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. System users are freed of redundant data entry and related time delays associated with most clinical research today. Velos integrates the clinical, administrative and financial information needs of research management, with an emphasis on flexibility and workflow. Founded in 1996, Velos, Inc. is privately held with headquarters in Fremont, California. For more information, visit http://www.velos.com/.
*This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.
SOURCE Velos, Inc.